Metreleptin Expanded Access Trial Status Now "No Longer Available"

On August 21, 2026, the clinical trial record for metreleptin was updated to reflect a status change. The trial, titled "Expanded Access for Metreleptin for the Treatment of Diabetes Mellitus and/or Hypertriglyceridemia Associated With Lipodystrophy," is registered under NCT00677313. This was an expanded access program rather than a phase-designated interventional trial. The listed status is now "no longer available." No phase was specified for this record. Metreleptin is a leptin analog, and this program had been intended for patients with diabetes mellitus and/or hypertriglyceridemia associated with lipodystrophy. The update reflects a change in the availability of this expanded access pathway, as recorded on ClinicalTrials.gov. No outcome data, efficacy findings, or safety results are included in this status update. The record does not state a reason for the change in availability. Individuals seeking information on metreleptin access should consult the official trial record and their healthcare provider for current details. This brief reports only the status change as listed and does not characterize the program's history beyond the information provided. For further background on this compound, readers can consult the compound overview.